Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** General Technical AgreementGeneral Technical Agreement • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This General Technical Agreement (this “Agreement”) is entered into as of July 24, 2016 (the “Effective Date”) by and between Oramed Ltd., a company organized under the laws of the State of Israel, with its offices at 2/4 Kefar Hi-tech, PO Box 39098, Jerusalem, 91390, Israel, and with the following facsimile number +972-2-566-0004 and email address josh@oramed.com (“Oramed”), and PREMAS Biotech Pvt. Ltd, a company organized under the laws of India, with its offices at Plot 77, Sector 4, IMT Manesar, Gurgaon 122050, Haryana, India, and with an email address prabuddha.kundu@premasbiotech.com (“Premas”).
Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)** AMENDMENT AGREEMENTAmendment Agreement • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
THIS AMENDMENT AGREEMENT, dated as of July 24, 2016, is entered into by and between Hefei Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui, China (“HTIT”); and Oramed Pharmaceuticals Inc., a Delaware corporation and Oramed Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 2/4 Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (collectively referred to as “Oramed”).
AGREEMENT AND AMENDMENT NO. 4Agreement • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This AGREEMENT AND AMENDMENT NO. 4 (this “Forth Amendment”) is made this 27 day of June, 2016 by and between ORAMED Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).
Second Amendment to Employment AgreementSecond Amendment to Employment Agreement • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This Second Amendment to the Employment Agreement (this “Second Amendment”) is entered into as of this 27 day of June 2016, by and between Joshua Hexter, an individual residing at Jerusalem, Israel (the “Executive”), and ORAMED Ltd., a company incorporated under the laws of the State of Israel, with an address at Hi-Tech Park 2/4 Givat Ram, Jerusalem, Israel 91390 (the “Company”).
Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”).** service Agreement between oramed ltd. and xertecs gmbhService Agreement • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
Oramed Ltd., a company organized under the laws of the State of Israel, with its offices at 2/4 Kefar Hi-tech, PO Box 39098, Jerusalem, 91390, Israel, hereafter referred to as “ORAMED”,
AGREEMENT AND AMENDMENT NO. 4Agreement And • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This AGREEMENT AND AMENDMENT NO. 4 (this “Forth Amendment”) is made this 27 day of June, 2016 by and between ORAMED Ltd., a company incorporated under the laws of the State of Israel, # 513976712 with an address at High-Tech Park 2/4, Givat Ram, Jerusalem, Israel 93706 (the “Company”), and KNRY, Ltd., a company incorporated under the laws of the State of Israel, # 513836502 with an address at 2 Elza Street, Jerusalem, Israel 93706 (the “Consultant”).
Confidential portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission (the “Commission”)**Agreement • November 25th, 2016 • Oramed Pharmaceuticals Inc. • Pharmaceutical preparations
This Agreement (the “Agreement”) is entered into as of June 3, 2016 (the “Effective Date”) between Hefei Tianhui Incubator of Technologies Co., Ltd., a corporation organized and existing under the laws of the People’s Republic of China (“PRC”) and having its principal place of business at No. 199 Fanhua Road, Heifei, Anhui, China (“HTIT”), and Oramed Ltd., a company organized and existing under the laws of the State of Israel and having a principal place of business at 2/4 Hi-Tech Park, PO Box 39098, Jerusalem, 91390, Israel (“Oramed”). HTIT and Oramed are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
